Skip to main content
Natco Pharma Ltd. logo

Natco Pharma Ltd. — Investor Relations & Filings

Ticker · NATCOPHARM ISIN · INE987B01026 LEI · 33580086GIBRWXSNGG39 BSE.NS Manufacturing
Open in API
Filings indexed 1,707 across all filing types
Latest filing 2021-10-05 Regulatory Filings
Country IN India
Listing BSE.NS NATCOPHARM

About Natco Pharma Ltd.

https://www.natcopharma.co.in/

Natco Pharma Ltd. is a vertically integrated organization focused on the development, manufacturing, and marketing of complex generics and active pharmaceutical ingredients (APIs). The company specializes in niche therapeutic areas, maintaining a leadership position in oncology and a significant presence in specialty segments such as hepatology, cardiology, and diabetology. Natco is recognized for its expertise in high-barrier-to-entry products, including complex oral solids and injectables. Its business model emphasizes research and development to deliver affordable versions of life-saving medicines globally. With a robust portfolio of finished dosage formulations and a strong supply chain for APIs, the company serves diverse international markets, including North America, Europe, and emerging economies, through strategic partnerships and direct distribution channels.

Recent filings

Filing Released Lang Actions
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, certifying the dematerialisation of securities for the quarter ended 30.09.2021. It is a formal attestation letter from a company to the company secretary regarding compliance with securities regulations. The document is short (1311 characters) and does not contain financial statements or detailed financial data. It is primarily a certification related to securities dematerialisation and regulatory compliance, not a financial report or announcement of financial results. Therefore, it fits best under Regulatory Filings (RNS), which covers officer certifications and miscellaneous regulatory documents that do not fit other categories.
2021-10-05 English
PCS Certificate for Transfer / Transmission/ Transposition for the half year ended September, 2021
Regulatory Filings
2021-10-05 English
Compliance Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended September, 2021
Regulatory Filings
2021-10-05 English
Press Release
Regulatory Filings Classification · 95% confidence The document text contains only placeholders for images and no substantive text content. The true document length is only 250 characters, which is very short and contains no financial data, report content, or announcements. It does not contain any report or announcement text, only image placeholders. Given the extremely short length and lack of content, this is likely a report publication announcement or a regulatory filing with no substantive report content. Following the MENU VS MEAL RULE, this cannot be classified as a full report. The best fit is Regulatory Filings (RNS) as a fallback category for miscellaneous filings without substantive content.
2021-10-01 English
NATCO Announces Launch of its 10mg strength for Everolimus Tablets (generic for Afinitor®) in the US market
Regulatory Filings
2021-10-01 English
Intimation of loss of share certificate
Regulatory Filings
2021-09-30 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.